Struggle for a hundred years, set sail on a new journey, a tour of China 丨 Seeing "Made in China" from a single pill-a leap from generic drugs to independent innovation

  Xinhua News Agency, Beijing, June 28th

 . "Title: Looking at "Made in China" from a single drug-a leap from generic drugs to independent innovation

  Xinhua News Agency reporter Chen Xiyuan

  The speed and quantity of COVID-19 vaccine research and development have always been in the world's top phalanx. The country has reported nearly 1.2 billion doses of vaccination... The "big test" of the global COVID-19 epidemic that has not been encountered in a century, China has submitted a qualified answer.

  As the “national team” for drug research and development, the new crown vaccine developed by Sinopharm was included in the WHO emergency use list on May 7. It became the first non-Western vaccine on the list, and it was also the first time that China’s vaccine against infectious diseases received the WHO emergency. Use authorization.

Independence and self-reliance

  On the centuries of the founding of the party, a "coating machine" in the shape of a drum was exhibited at the Sinopharm Group, quietly telling the history of the Chinese people's fight against infectious diseases.

  This machine is used to produce "sugar pills" for polio vaccine.

In the 1950s, the polio epidemic spread across the country, and most of the infected were children. It is possible that the children’s legs, feet and arms could not move overnight.

If inflammation occurs in the extension of the brain, the child is more likely to be life-threatening.

  At that time, Gu Fangzhou, who was in his 30s, was in danger and was ordered to start research on polio.

  "The world's science and technology, after all, has to be self-reliant." Tens of kilometers away from Kunming city, Gu Fangzhou led people to dig holes, build houses, and independently develop vaccines.

In the 1960s, sugar pill vaccines produced by "coating machines" began to be supplied to the whole country on a large scale.

  Since 1994, there have been no cases of polio caused by native wild viruses in our country, and the "sugar pill" has become a "sweet" memory of the childhood of generations of Chinese people.

  Maintaining the health of the people has been the constant pursuit of the Chinese Communist Party for a century.

During the arduous revolutionary war years, the Xiaojing Red Army Hospital on Jinggang Mountain lacked medicines. The medical staff collected Chinese herbal medicines and gave them to the wounded after suffering. In Qiongya, Hainan, the Red Army soldiers discovered that a medicinal plant that was half a human tall was good for eating. It can cure diseases and call it a "revolutionary dish."

  The time comes to the beginning of 2020. In the face of the sudden new crown pneumonia epidemic, China insists that the people are supreme and life is supreme. In February of that year, a vaccine research and development team was established and multiple technical routes were deployed.

  From the start of the new crown vaccine project to the world’s first clinical research, it only took 2 months; to the first emergency use of vaccines in my country’s history, it only took 4 months; to the first overseas phase III clinical trials of vaccines in my country’s history, only It took 5 months; it only took 11 months to get the conditional listing approval.

  At present, while strengthening the domestic immune barrier, my country has two vaccines including Sinopharm and Kexing on the WHO emergency use list, and four vaccines on the list of new crown vaccine products available for export, in order to build human health and health. The community contributes to China's strength.

The original innovative drugs are entering the harvest period

  Not only are there "national teams", more and more pharmaceutical companies are also achieving results at the forefront of innovation.

  In late June, the combined use of Daboshu and Dayoutong was approved for marketing, becoming the world's first PD-1 immune combination therapy approved for liver cancer patients.

The two drugs developed by Cinda Biological are the results of the major scientific and technological project of "Major New Drug Creation".

  After the founding of New China, my country gradually had an independent industrial system, and the shortage of medicines and medicines was alleviated.

By the turn of the century, my country's pharmaceutical industry was once one of the fastest-growing industries in the national economy, but most of its products were generic drugs and lacked patent protection.

  In 2008, as part of my country's mid- and long-term scientific and technological development plan, multiple departments implemented major scientific and technological projects of "Major New Drug Creation and Manufacturing" to promote the gradual transformation of my country's new drug development from imitation-based to creation-based.

  In 2011, my country's first small-molecule targeted anti-cancer drug icotinib hydrochloride with completely independent intellectual property rights was born in Zhejiang. Its listing has prompted a price reduction of more than 50% of relevant foreign patent drugs in China.

  During the "13th Five-Year Plan" period, more than one-fifth of the country's first-class innovative drugs were cultivated in Shanghai alone.

In 2020, the scale of Shanghai Pudong's biopharmaceutical industry will exceed 80 billion yuan, and a total of 11 Class I new drugs will be listed.

  "In order to allow the majority of patients to use good Chinese medicines as soon as possible, the scientific research team has been continuously researching drug innovation for more than ten years or even decades, and has achieved breakthrough results by putting the'cold bench on the hot bench'." Grinding a sword, with the initial establishment of the national drug innovation technology system, the reform of the drug review and approval system continues to deepen, and the original innovative drugs are entering the harvest period.

Good medicine is more affordable

  With good medicine, the key is to make it accessible and affordable to the people.

Focusing on the people and seeking happiness for the Chinese people, the original intention of the Communist Party of China has not changed.

  On June 23, the fifth batch of national-organized centralized drug procurement was opened in Shanghai. The 251 products to be selected were reduced by an average of 56%, which was the largest national-organized centralized drug procurement.

  The normalized and institutionalized implementation of centralized national drug procurement has transformed institutional advantages into governance efficiency and effectively reduced the burden on patients.

Hu Yinglian, a professor at the Central Party School (National School of Administration), believes that drug governance has changed from focusing on treating diseases to focusing on people's health, paying more attention to drug quality and safety and promoting innovation.

  Adhere to the "four aspects" of scientific and technological innovation, including "facing the lives and health of the people."

Starting from the urgent and long-term needs of the country, a number of key core technologies in the fields of medicines, medical devices, medical equipment, vaccines, etc. are accelerating breakthroughs.

  Looking forward to the "14th Five-Year Plan", it has become a consensus to build a healthy China, deepen the reform of the medical and health system, and lead the high-quality development of the medical field with innovation.

The state will also build a support platform for Chinese medicine science and technology, reform and improve the Chinese medicine review and approval mechanism, and promote the research and development, protection and industrial development of new Chinese medicines.